Stereotactic Biopsy for Brainstem Lesions: A Meta-analysis with Noncomparative Binary Data

Lin He\textsuperscript{1,†}, Dongjie He\textsuperscript{1,†}, Yuhong Qi\textsuperscript{1}, Jiejing Zhou\textsuperscript{1}, Canliang Yuan\textsuperscript{1}, Hao Chang\textsuperscript{1}, Qiming Wang\textsuperscript{1}, Gaiyan Li\textsuperscript{1}, and Qiuju Shao\textsuperscript{1}

Abstract

Objectives: To evaluate the diagnostic yield and safety of brainstem stereotactic biopsy for brainstem lesions.

Methods: We performed a meta-analysis of English articles retrieved from the PubMed, Web of Science, Cochrane Library, and APA psycInfo databases up to May 12, 2021. A binary fixed-effect model, the inverse variance method, or a binary random-effect model, the Dersimonian Laird method, were utilized for pooling the data. This meta-analysis was registered with INPLASY, INPLASY202190034.

Findings: A total of 41 eligible studies with 2792 participants were included. The weighted average diagnostic yield was 97.0\% (95\% confidence interval [CI], 96.0-97.9\%). The weighted average proportions of temporary complications, permanent deficits, and deaths were 6.2\% (95\% CI, 4.5-7.9\%), .5\% (95\% CI, 0-2.8\%), and .3\% (95\% CI, 0-1.5\%), respectively. The subgroup analysis indicated a nearly identical weighted average diagnostic yield between MRI-guided stereotactic biopsy and CT-guided stereotactic biopsy (95.9\% vs 95.8\%) but slightly increased proportions of temporary complications (7.9\% vs 6.0\%), permanent deficits (1.9\% vs .2\%), and deaths (1.1\% vs .4\%) in the former compared to the latter. Moreover, a greater weighted average diagnostic yield (99.2\% vs 97.6\%) and lower proportions of temporary complications (5.1\% vs 6.8\%) and deaths (.7\% vs 1.5\%) were shown in the pediatric patient population than in the adult patient population.

Conclusions: Brainstem stereotactic biopsy demonstrates striking accuracy plus satisfying safety in the diagnosis of brainstem lesions. The diagnostic yield, morbidity, and mortality mildly vary based on the diversity of assistant techniques and subject populations.

Keywords

stereotactic biopsy, brainstem lesion, diagnostic yield, safety, meta-analysis

Key Points

(1) Combined with multiple new techniques, brainstem stereotactic biopsy is efficient and safe to diagnose brainstem lesions in adults and children.

(2) CT-guided stereotactic biopsy shows a diagnostic yield similar to that of MRI-guided stereotactic biopsy but with improved safety.

(3) Brainstem stereotactic biopsy reveals more effectiveness and safety to diagnose brainstem lesions in the pediatric patient population than in the adult patient population.

(4) When modifying the combined techniques and/or participant populations, the diagnostic yield, morbidity,

\begin{itemize}
  \item [\textsuperscript{1}]Department of Radiotherapy, Tangdu Hospital, Air Force Military Medical University, Xi’an, China
  \item [\textsuperscript{†}]These authors are contributed equally to this work.
\end{itemize}

Corresponding Author:

Qiuju Shao Department of Radiotherapy Tangdu Hospital Air Force Military Medical University, No,568 Xinsi Road, Baqiao, Xi’an, Shanxi 710032, China.

Email: shaoqfmmu@163.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Introduction

Since the advent of stereotactic biopsy for more than 7 decades, its application fields and clinical utilities have been gradually expanded in combination with an increasing body of novel adjunctive tools (e.g., CT, MRI, PET-CT, and robot assistance). With the advantages of accurate positioning, less trauma, and contributions to pathological diagnosis, stereotactic biopsy has become the gold standard for diagnosing brain tumors at the end of the 20th century.1 Stereotactic localization was first applied to biopsy and radiofrequency treatment of brainstem lesions by Gleason et al. in 1978.2 Approximately 15% of pediatric and 2% of adult intracranial space-occupying lesions are brainstem lesions.3 Brainstem stereotactic biopsy is performed through 4 main routes: contralateral extraventricular transfrontal approach, ipsilateral transfrontal approach, transtentorial approach, and suboccipital transcerebellar approach, which appear to have no significant difference concerning the diagnostic yield and total complications.4,5 Given that the brainstem is the densest distribution area of cerebral nuclei, many neurosurgical teams are concerned about the potential risks of brainstem stereotactic biopsy and discern no direct benefits to patients, thus they are prone to decline the implementation of this procedure. In 1993, the Children’s Cancer Group-9882 study6 demonstrated the high specificity of MRI in diagnosing brainstem glioma and made no alteration to the treatment paradigm because of histological confirmation, thus they suggested obviating the usage of biopsy before radiotherapy. Since then, there has been a paucity of brainstem stereotactic biopsies for nearly 1 decade.

Over time, this operation has been refueled by the following 3 factors. First, a large number of studies together confirm that there are more than 15–20% inconsistent outcomes between preoperative MRI diagnosis and postoperative pathological findings7-11; second, many benign brain lesions (e.g., ischemia, demyelination, radionecrosis, vascular malformedion, abscess, tuberculoma, granuloma, encephalitis, and cystic lesions)12,13 and several malignant tumors (e.g., glioma, metastasis, lymphoma, epidermoid, and primitive neuroectodermal tumor)14 may mimic each other in radiological imaging; and finally, the diagnosis and treatment of brainstem tumors increasingly depend on the molecular diagnostics, for example, the 3 molecularly distinct subgroups (H3-K27 M, Silent, and MYCN) of the diffuse intrinsic pontine gliomas that can be utilized as new therapeutic targets.15 Therefore, stereotactic biopsy is extremely crucial for the definitive diagnosis of space-occupying lesions of the brainstem, the molecular classification of brainstem neoplasms, and the development of new targeted therapies.

Brainstem stereotactic biopsy can be operated with CT-, MRI-, or PET-CT-guided framed navigation or with robotic frameless assistance.16-19 Again, thanks to these new techniques, contemporary brainstem stereotactic biopsy shows high diagnostic yield and good safety. Two previous systematic reviews and meta-analyses investigating the diagnostic value and safety of brainstem stereotactic biopsy in brainstem tumors by Dr Ruge’s team both found a high weighted average proportion of diagnostic success (96.1-96.2%) coupled with low overall morbidity (6.7-7.8%), permanent morbidity (.6-1.7%), and mortality (.6-.9%).10,21 However, none of the 2 systematic reviews performed further subgroup analyses in light of populations and biopsy methods. We herein conducted a meta-analysis to explore the diagnostic yield and safety of brainstem stereotactic biopsy for brainstem lesions. Additionally, subgroup analysis of the operation with different biopsy strategies (i.e., CT guidance, MRI guidance, framed navigation, and transcerebellar approach) and in diverse populations (i.e., adults and children) was performed to gauge its clinical utility.

Materials and Methods

Our work abided by the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines.22,23 This meta-analysis was registered with INPLASY, INPLASY202190034. There was no need for Ethical or Institutional Review Board Approval for the study design due to the nature of our work.

Literature Search

We conducted a computerized search in the PubMed, Web of Science, Cochrane Library, and APA psycINFO databases to identify English-language articles up to May 12th, 2021. The following terms were used: (“brainstem lesion [MeSH]” or ((brainstem or (brain stem) or pons or pontine or mesencephalon or midbrain or (medulla oblongata)) AND (tumor or tumor or cancer or neoplasm or glioma or carcinoma)) AND (biopsy or biopsies) AND (diagnosis or diagnostic or diagnose).

Inclusion and Exclusion Criteria

Clinical articles evaluating the diagnostic yield and/or safety of brainstem stereotactic biopsy were considered to be eligible for our purposes. Additionally, potential studies were required to meet the following inclusion criteria: (1) populations—patients with brainstem mass lesions, regardless of age; and (2) reference standards—the ultimate diagnosis was compared with histopathologic results plus clinical assessments. Retrieved citations that met any of the following criteria were removed: (1) article type—reviews, case reports, case series that involved fewer than 10 patients, editorials, letters, comments, and conference papers; (2) diagnostic methods—only radiological images but without pathological examinations; and (3) overlapping study populations.
Data Extraction and Quality Assessment

We extracted the following data from the included studies by using a standardized form: (1) study characteristics—family name of the first author, publication year, study duration, original country or area, study type, number of patients, and tumor/total ratio; (2) demographic characteristics—mean age, patient cohort (i.e., pediatric patient population and adult patient population) and male/female ratio; (3) examination characteristics—guided techniques or assistant methods; and (4) outcome characteristics—diagnostic yield and safety, comprising temporary complications, permanent deficits, and deaths. The overall survival (OS) of the included subjects was also assessed in our study. Two coauthors (Dr Dongjie He and Dr Gaiyan Li) independently assessed the literature search, study selection, and data extraction. If there were any inconsistencies, they were addressed by a third coauthor (Dr Yuhong Qi).

Quality assessment of the analyzed studies was not judged because the noncomparative data did not present any risk of publication bias.

Data Synthesis and Statistical Analysis

The primary outcome was the weighted average diagnostic yield of stereotactic biopsy for brainstem lesions, and the secondary outcomes were the weighted average proportions of temporary complications, permanent deficits, and deaths. The crude proportions with 95% confidence intervals (CIs) in all analyzed studies were independently calculated and then pooled together to the weighted average values. The number of events, if not provided by the publication, was calculated in light of the endpoint percentage or other relevant information. The heterogeneity that implicated the degree of variability in results across the included studies was assessed by Cochran’s Q test and Higgins I² statistic test; P < .10 suggested significant heterogeneity, and different cutoff intervals of I² values at 0–25%, 25–50%, 50–75%, and 75–100% corresponded to nonsignificant, moderate, substantial, and considerable heterogeneity, respectively. When the heterogeneity test indicated no statistical significance (P ≥ .1), a binary fixed-effect model, the inverse variance method, was used to pool data, and if not so, a binary random-effect model, the DerSimonian Laird method, was employed. All statistical analyses were conducted by the software Open Meta-Analyst (http://www.cebm.brown.edu/openmeta/download.html).

Results

Literature Search

A PRISMA flow diagram of the literature screening selection is shown in Figure 1. We obtained 5012 citations from the PubMed, Web of Science, Cochrane Library, and APA psycInfo databases and excluded 303 reduplications, 22

![Figure 1. PRISMA flow diagram of study selection.](image-url)
Table 1. Characteristics of Included Studies in the “Study-Level” Analysis.

| Study (Year) | Study Duration | Original Nation | Biopsy technique† | Patient Cohort | Mean Age | Total Sample (n) | Definitive Diagnosis (n) | Permanent Deficits (n) | Temporary Complications (n) | Death (n) | Tumor/Total* Ref |
|--------------|----------------|-----------------|-------------------|---------------|----------|-----------------|--------------------------|--------------------------|----------------------------|-----------|----------------|
| Bahrami (2020) | 2006–2016 | Iran | MRI; F; TC | A+C | 35.4 | 39 | 38 | 0 | 0 | 0 | 27/38 |
| Shad (2005) | NA | UK | CT; F; TF | A | 47.0 | 13 | 12 | 0 | 3 | 0 | 11/12 |
| Puget (2015) | 2002–2015 | France | MRI/CT; F; TC | C | 6.7 | 130 | 130 | 0 | 5 | 0 | 130/130 |
| Pincus (2006) | NA | USA | 3D; F; TF/TC | C | 12.8 | 10 | 10 | 0 | 1 | 0 | 10/10 |
| Cheng (2020) | 2015–2017 | China | MRI/CT; F; TC | A+C | 32.7 | 111 | 106 | NA | NA | 3 | 99/106 |
| Dellaretti (2011) | 1988–2007 | France | MRI; F; TF/TC | C | 6.0 | 130 | 120 | 0 | 4 | 0 | 130/130 |
| Dellaretti (2012) | 1988–2007 | France | MRI; F; TF/TC | A | 41.0 | 96 | 92 | 0 | 9 | 1 | 82/92 |
| Cartmill (1999) | 1990–1995 | UK | CT; F; TC | C | 6.0 | 18 | 18 | 0 | 5 | 0 | 18/18 |
| Wang (2015) | 2001–2012 | USA | NA; NA; TC | C | 8.8 | 15 | 15 | 0 | 3 | 0 | 15/15 |
| Birski (2021) | 2007–2018 | Poland | MRI; F; NA | A | 48.0 | 85 | 83 | 0 | 10 | 2 | 83/83 |
| Hamisch (2019) | 1996–2015 | Germany | MRI/CT; F; TT | A+C | 48.5 | 498 | 494 | 2 | 48 | 0 | 431/494 |
| Lara-Almunia (2019) | 1988–1995 | UK | CT; F; NA | A+C | 43.0 | 180 | 180 | 0 | 5 | 0 | 180/180 |
| Dellaretti (2020) | 2008–2018 | Brazil | MRI/CT; F; TF/TC | A+C | 29.4 | 31 | 26 | 0 | 3 | 0 | 26/26 |
| Ryken (1992) | 1985–1990 | USA | NA; NA; NA | A+C | 43.8 | 11 | 9 | 0 | 1 | 0 | 9/9 |
| Puget (2012) | NA | France | NA; F; TC | C | NA | 90 | 90 | 0 | 4 | 0 | 90/90 |
| Akay (2019) | 2011–2018 | Turkey | MRI; F; TF/TC | A+C | 43.8 | 18 | 18 | 0 | 2 | 0 | 18/18 |
| Morais (2020) | 2008–2018 | Brazil | MRI; F; TC | C | 8.8 | 26 | 22 | NA | NA | 0 | 21/22 |
| Gupta (2018) | 2011–2015 | USA | MRI; F; TC | C | 6.4 | 50 | 46 | 0 | 3 | 0 | 46/46 |
| Kondziolka (1995) | 1996–1995 | France | MRI/CT; F; NA | A+C | 40 | 38 | 38 | 0 | 1 | 0 | 38/38 |
| Pirotte (2007) | 1995–2006 | Belgium | PET; F; TF/TC | C | 8.2 | 20 | 20 | 1 | 1 | 0 | 20/20 |
| Gupta (2020) | 2015–2020 | USA | Robot; FFL; TC | C | 9.1 | 22 | 21 | 0 | 4 | 0 | 20/21 |
| Dawes (2015) | 2015–2017 | UK | Robot; F; TC | C | 10.0 | 11 | 10 | 0 | 0 | 0 | 9/10 |
| Rachinger (2009) | 1998–2007 | Germany | MRI/CT; F; TF/TC | A+C | 43.0 | 46 | 46 | 0 | 1 | 0 | 43/46 |
| Rajeshvar (2010) | 1988–2008 | India | CT; F; TF/TC | C | 9.25 | 106 | 106 | 0 | 11 | 0 | 96/106 |
| Gonçalves-Ferreira (2003) | 1992–2001 | Portugal | MRI/CT; F; TF/TC | A+C | 43.0 | 30 | 28 | 0 | 2 | 0 | 18/28 |
| Dellaretti (2012) | 1984–2007 | Brazil | MRI; F; TF/TC | NA | NA | 135 | 135 | 0 | 13 | 0 | 135/135 |
| Valdés-Gorcia (1998) | 1989–1997 | Mexico | MRI/CT; F; NA | C | 6.3 | 30 | 29 | 0 | 0 | 0 | 1/29 |
| Samadani (2006) | 1996–2003 | USA | MRI; F; NA | A+C | 46.0 | 12 | 12 | 0 | 12 | 0 | 12/12 |
| Quick-Weller (2016) | 1994–2015 | Germany | MRI; F; TF/TC | A+C | 33.0 | 26 | 26 | 0 | 5 | 0 | 26/26 |
| Manoj (2014) | 1994–2009 | India | MRI/CT; F; NA | A+C | 32.11 | 82 | 75 | 0 | 5 | 0 | 82/75 |
| Steck (1995) | 1983–1993 | USA | CT; F; TF/TC | A+C | 39.5 | 24 | 23 | 0 | 2 | 0 | 23/23 |
| Haegele (2010) | 2004–2006 | France | Robot; FL; TF/TC | A+C | 32.0 | 15 | 15 | 1 | 2 | 0 | 9/13 |
| Coffey (1985) | 1982–1984 | USA | CT; F; TF/TC | A | 56.5 | 12 | 12 | 0 | 0 | 0 | 10/12 |
| Parker (1999) | 1991–1996 | USA | MRI/CT; F; TC | A+C | 25.3 | 18 | 18 | 0 | 2 | 0 | 17/18 |
| Chico-Ponce de León (2003) | 1989–2002 | Mexico | MRI/CT; F; TF/TC | C | 7.0 | 50 | 50 | 0 | 50 | 0 | 50/50 |
| Hood (1986) | 1984–1985 | USA | CT; F; TF/TC | A+C | 15.5 | 12 | 12 | 1 | 0 | 0 | 12/12 |
| Abematheyr (1989) | 1984–1988 | USA | MRI/CT; F; TC | A+C | 34.0 | 26 | 26 | 0 | 0 | 0 | 26/26 |
| Mathisen (1987) | NA | Norway | CT; F; TC | A+C | 52.0 | 13 | 13 | 1 | 0 | 0 | 13/13 |
| Sanai (2008) | NA | USA | MRI/CT; F; TC | A | 52.0 | 13 | 13 | 1 | 0 | 0 | 13/13 |
| Quick-Weller (2018) | 2013–2015 | Germany | NA; F; NA | A | 63.0 | 43 | 43 | 0 | 1 | 0 | 43/43 |
| Yu (1998) | 1991–1995 | China | CT; F; NA | A+C | 39.3 | 310 | 299 | 0 | 5 | 0 | 257/299 |

*The calculation of the tumor/total ratio is based on the biopsy results.
†Information on the biopsy techniques details the guided techniques, navigation methods, and biopsy approaches.
Abbreviations: NA, not applicable; MRI, magnetic resonance imaging; CT, computerized X-ray tomography; PET, positron emission tomography; 3D, three-dimensional localization; F, framed; FL, frameless; TC, transcerebellar; TF, transfrontal; TT, transtentorial; A, adults; C, children.
conference papers, 571 reviews, 449 case reports, and 228 non-English publications. The remaining 3439 citations were assessed by title and abstract screening, and 3391 of them were removed; fundamental characteristics of the abstracts were judged with respect to the inclusion and exclusion criteria, and full-length articles were chosen. After full-text scrutinization, 7 of the remaining 48 articles were further omitted for the following reasons: (1) 3 articles investigated intraoperative or postoperative biopsy; (2) 1 article involved space-occupying lesions of non-brainstem; (3) 1 article involved non-stereotactic biopsy; and (4) 1 article presented no available data. Ultimately, 41 articles including 2792 unique patients with brainstem lesions were eligible for the meta-analysis.1,4,7,8,13,14,16-19,26-56

Characteristics of the Studies Included for Meta-analysis

The characteristics of the 41 eligible studies in the “study-level” analysis are outlined in Table 1, and those in the “patient-level” analysis are summarized in Table 2. The retrospective cohort studies (n = 32)1,4,7,8,13,14,16,17,19,26-29,37,42-52 outnumbered the prospective cohort studies (n = 9)18,27,28,38-41,53,55; the publication year ranged from 1986 to 2021 (median: 2010); USA ranked at the first place of all original nations (n = 13)7,8,13,19,33,35,38,39,45,48,50,52,54; from all available studies, the median value of the mean age of included subjects was 32.7 (6-63), that of the male/female ratio was 1.3 (.5-4.5), and that of the tumor proportion was 93.2% (61.5-100.0%); and the median OS of included subjects was provided by 11 publications.7,18,19,28,32,33,35,37,41,42,52 with the median value of 11.0 (7.5-28.0). Additionally, Table 1 summarizes the details of diagnostic yield and safety from all analyzed studies.

Diagnostic Yield

All 41 studies were involved in analyzing the diagnostic yield of brainstem stereotactic biopsy.1,4,7,8,13,14,16-19,26-56 The pooled result showed a weighted average diagnostic yield of 97.0% (95% CI, 96.0–97.9%) (Figure 2). The subgroup analysis indicated that the weighted average diagnostic yields with the CT-guided technique, MRI-guided technique, framed navigation, and transcerebellar approach were 95.8% (95% CI, 93.0–98.6%), 95.9% (95% CI, 93.7–98.1%), 97.1% (95% CI, 96.1–98.1%), and 99.1% (95% CI, 98.3–99.9%), respectively. The weighted average diagnostic yield in the pediatric patient population (99.2%; 95% CI, 98.5–99.9%) was numerically higher than that in the adult patient population (97.6%; 95% CI, 96.0–99.1%) (Table 3).

Temporary Complications

We collected 34 eligible studies1,4,7,8,13,14,17-19,26-28,30-36,38-44,46-50,52,54,56 to investigate the temporary complications caused by brainstem stereotactic biopsy. The pooled result indicated that the weighted average proportion of temporary complications was 6.2% (95% CI, 4.5–7.9%) (Figure 3). The subgroup analysis indicated that the weighted average proportions of temporary complications with the CT-guided technique, MRI-guided technique, framed navigation, and transcerebellar approach were 6.0% (95% CI, 1.8–10.1%), 7.9% (95% CI, 3.7–12.0%), 6.0% (95% CI, 4.2–7.7%), and 3.6% (95% CI, 1.9–5.4%), respectively. The weighted average proportion in the pediatric patient population (6.8%; 95% CI, 2.4–11.2%) was 1.7% less than that in the adult patient population (5.1%; 95% CI, 3.2–6.9%) (Table 3).

Permanent Deficits

Equivalently, these 34 articles1,4,7,8,13,14,17-19,26-28,30-36,38-44,46-50,52,54,56 were further included in the analysis of brainstem stereotactic biopsy-caused permanent deficits. The pooled result showed that the weighted average proportion of permanent deficits was .5% (95% CI, .2–.8%) (Figure 4). The subgroup analysis suggested that the weighted average proportions of permanent deficits with the CT-guided technique, MRI-guided technique, framed navigation, and transcerebellar approach were .2% (95% CI, .0–.7%), 1.9% (95% CI, .1–3.7%), .4% (95% CI, .2–.7%), and .7% (95% CI, .0–1.5%), respectively. The weighted average proportion in the pediatric patient population (.6%; 95% CI, .0–1.3%) was similar to that in the adult patient population (.3%; .0–.7%) (Table 3).

Deaths

There was concern regarding brainstem stereotactic biopsy-caused mortality, for which 39 articles1,4,7,8,13,14,16-19,26-52,54,56 were involved in the analysis. The pooled result in Figure 5 revealed that the weighted average proportion of deaths was .3% (95% CI, .1–.5%). The subgroup analysis indicated that the weighted average proportions of deaths with the CT-guided technique, MRI-guided technique, framed navigation, and transcerebellar approach were .4% (95% CI, .0–.7%), 1.1% (95% CI, .1–2.1%), .3% (95% CI, .1–.5%), and .7% (95% CI, .0–1.5%), respectively. The weighted average proportion in the pediatric patient population (.7%; 95% CI, .1–1.3%) seemed to be safer than that in the adult patient population (1.5%; 95% CI, .2–2.8%), with a .8% decreased proportion (Table 3).

Heterogeneity

The majority of analyses found insignificant heterogeneity across their involved clinical studies, and the minority of analyses showed moderate to considerable heterogeneity as follows: (1) diagnostic yield (I² = 53.29%); (2) permanent deficits (I² = 57.55%); (3) diagnostic yield of CT-guided technique (I² = 74.61%), and framed navigation (I² = 55.29%); (4) temporary
Table 2. Characteristics of Included Studies in the “Patient-Level” Analysis.

| Characteristic                           | Studies, no. (%) (N = 41) | Analyzed Subjects, no. (%) (N = 2792) |
|-----------------------------------------|---------------------------|--------------------------------------|
| Study type                              |                           |                                      |
| Prospective cohort                      | 32 (78.0)                 | 382 (13.7)                           |
| Retrospective cohort                    | 9 (22.0)                  | 2410 (86.3)                          |
| Publication year, median (range), y     | 2010 (1986–2021)          |                                      |
| Mean age, median (range), y*            | 32.7 (6–63)               |                                      |
| Male/female ratio, median (range)*      | 1.3 (.5–4.5)              |                                      |
| Tumor proportion, median (range), %     | 93.2 (61.5–100.0)         |                                      |
| Original nation                         |                           |                                      |
| Iran                                    | 1 (2.4)                   | 39 (1.4)                             |
| UK                                      | 3 (7.3)                   | 42 (1.5)                             |
| France                                  | 5 (12.2)                  | 375 (13.4)                           |
| USA                                     | 13 (31.7)                 | 304 (10.9)                           |
| China                                   | 2 (4.9)                   | 421 (15.1)                           |
| Poland                                  | 1 (2.4)                   | 85 (3.0)                             |
| Germany                                 | 4 (9.8)                   | 613 (22.0)                           |
| Spain                                   | 1 (2.4)                   | 407 (14.6)                           |
| Brazil                                  | 3 (7.3)                   | 180 (6.4)                            |
| Turkey                                  | 1 (2.4)                   | 18 (.6)                              |
| Belgium                                 | 1 (2.4)                   | 20 (.7)                              |
| India                                   | 2 (4.9)                   | 188 (6.7)                            |
| Portugal                                 | 1 (2.4)                   | 30 (1.1)                             |
| Mexico                                  | 2 (4.9)                   | 80 (2.9)                             |
| Norway                                  | 1 (2.4)                   | 29 (1.0)                             |
| Patient cohort                          |                           |                                      |
| Adult                                   | 7 (17.1)                  | 308 (11.0)                           |
| Children                                | 14 (34.1)                 | 622 (22.3)                           |
| Adult + children                        | 19 (46.3)                 | 1739 (62.3)                          |
| No details                              | 1 (2.4)                   | 123 (4.4)                            |
| Guidance technique                      |                           |                                      |
| MRI                                     | 9 (22.0)                  | 434 (15.5)                           |
| CT                                      | 10 (24.4)                 | 971 (34.8)                           |
| Robot-assistant                         | 3 (7.3)                   | 48 (1.7)                             |
| PET                                     | 1 (2.4)                   | 20 (.7)                              |
| MRI/CT                                  | 12 (29.3)                 | 1150 (41.2)                          |
| 3D                                      | 1 (2.4)                   | 10 (.4)                              |
| No details                              | 4 (9.8)                   | 159 (5.7)                            |
| Navigation methods                      |                           |                                      |
| Framed                                  | 34 (82.9)                 | 2721 (97.5)                          |
| Frameless                               | 1 (2.4)                   | 15 (.5)                              |
| Framed/frameless                        | 2 (4.9)                   | 133 (4.8)                            |
| No details                              | 4 (9.8)                   | 103 (3.7)                            |
| Biopsy approaches                       |                           |                                      |
| Transfrontal approach                   | 2 (4.9)                   | 53 (1.9)                             |
| Transtentorial approach                  | 2 (4.9)                   | 516 (18.5)                           |
| Transcerebellar approach                 | 12 (29.3)                 | 469 (16.8)                           |
| Transfrontal/transcerebellar approach    | 17 (41.5)                 | 774 (27.7)                           |
| No details                              | 8 (19.5)                  | 980 (35.1)                           |
| Median OS assessment                    |                           |                                      |
| Yes                                     | 11 (26.8)                 | 432 (15.5)                           |
| No                                      | 30 (73.2)                 | 2360 (84.5)                          |
| Median OS, median (range), m*           | 11.0 (7.5–28.0)           |                                      |

*The calculation of the median value is based on the provided data from the included studies.; Abbreviations: MRI, magnetic resonance imaging; CT, Computerized X-ray tomography; PET, positron emission tomography; 3D, three-dimensional graphics workstation; OS, overall survival.
complications of CT-guided technique ($P = .009$, $I^2 = 62.42\%)$, MRI-guided technique ($P = .019$, $I^2 = 60.58\%)$, framed navigation ($P < .001$, $I^2 = 60.72\%$), and in the adult patient population ($P = .084$, $I^2 = 48.52\%$); and (5) permanent deficits of MRI-guided technique ($P = .051$, $I^2 = 52.21\%$).

**Discussion**

Despite the refined sensitivity and specificity of modern neuroimaging technologies, only relying on imaging results to diagnose brainstem lesions gives rise to a nonnegligible misdiagnosis rate, ranging from 10% to 20%. With the popularity of molecularly targeted therapy for cancers, the selection of well-matched targeted agents is dependent on the biologically diagnostic outcome of tumor samples; additionally, the demonstrations of different molecular phenotypes of brainstem tumors require a high level of histological diagnosis for space-occupying lesions. Accurate tissue diagnosis may alter the subsequent treatment intervention and prognosis. However, correct surgical algorithms, appropriate biopsy techniques, and adequate sample acquisition affect the diagnostic yield and safety of brainstem stereotactic biopsy. Involving recently published literature spanning more than 3 decades, our meta-analysis confirms a maximal diagnostic yield plus the minimal morbidity and mortality of brainstem stereotactic biopsy. These optimistic results can obviate the concerns of most neurosurgical teams who consider brainstem stereotactic biopsy to be detrimental to patients and support the successful histologic diagnosis of brainstem lesions.

![Coupled forest plot of diagnostic yield. A binary random-effect model, the Dersimonian Laird method, was used to pool the data because of substantial heterogeneity.](image-url)
Some clinical studies have revealed the reliability of brainstem stereotactic biopsy for brainstem lesions, with a diagnostic yield of 81.8–100.0%.\textsuperscript{17,34,35} The weighted average diagnostic yield of brainstem stereotactic biopsy for brainstem lesions is 97%, which mirrors the outcomes of the 2 aforementioned meta-analyses.\textsuperscript{20,21} Brainstem stereotactic biopsy combined with other techniques yields the achievement of tissue samples from children and adults for histopathologic diagnosis. Multiple studies have suggested that the diagnostic yield of brainstem stereotactic biopsy with CT guidance is 90.4–100.0%\textsuperscript{16,42} and that with MRI guidance is 84.6–100.0%.\textsuperscript{37,46} Furthermore, according to different patient cohorts, other studies noted that the diagnostic yields of brainstem stereotactic biopsy in the pediatric and adult patient populations were 84.6–100.0%\textsuperscript{28,37} and 80.0–100.0%,\textsuperscript{49,55} respectively. The present subgroup analysis signifies a nearly identical diagnostic yield between CT-guided and MRI-guided stereotactic biopsy and a 1.6% increment in the weighted average diagnostic yield in the pediatric patient population compared to the adult patient population. Our findings suggest that brainstem stereotactic biopsy to definitively diagnose brainstem lesions is somewhat more effective in children than in adults.

Brainstem stereotactic biopsy is safe for the diagnosis of brainstem lesions, with a low proportion of temporary complications (e.g., facioplegia, facial pain, changes in blood pressure and heart rate, and breathing difficulty).\textsuperscript{26,36,56} Our study reaffirms the safety of this procedure in that the weighted average proportion of temporary complications is 6.2%. The diverse guided techniques and different analyzed patient cohorts may slightly influence the safety of brainstem stereotactic biopsy. In our subgroup analysis, the imaging technique using MRI guidance manifests a 1.9% higher proportion of the weighted average temporary complications than that using CT guidance, and the adult patient population has a 1.7% higher proportion than the pediatric patient population. Notably, the heterogeneity test of the subgroup analyses of the CT-guided technique, MRI-guided technique,

### Table 3. Subgroup Analysis With the Different Assistant Techniques and Patient Populations.

| Subgroup Analysis                     | Weighted Average Proportion (95% CI) | Included Studies (N) | Event/Total (N) | Effect Model | Heterogeneity Test | I², % | P Value |
|---------------------------------------|-------------------------------------|----------------------|----------------|--------------|-------------------|-------|---------|
| **Diagnostic yield**                  |                                     |                      |                |              |                   |       |         |
| CT-guided technique                   | 95.8% (93.0-98.6%)                  | 10                   | 916/971        | Random       | 74.61             | < .001|         |
| MRI-guided technique                  | 95.9% (93.7-98.1%)                  | 8                    | 295/311        | Fixed        | .00               | .615  |         |
| Framed navigation                     | 97.1% (96.1-98.1%)                  | 31                   | 2444/2541      | Random       | 55.29             | < .001|         |
| Transcerebellar approach              | 99.1% (98.3-99.9%)                  | 13                   | 466/479        | Fixed        | .00               | .362  |         |
| Adult patients                        | 97.6% (96.0-99.1%)                  | 9                    | 344/359        | Fixed        | .00               | .352  |         |
| Pediatric patients                    | 99.2% (98.5-99.9%)                  | 15                   | 647/663        | Fixed        | .00               | .309  |         |
| **Temporary complications**           |                                     |                      |                |              |                   |       |         |
| CT-guided technique                   | 6.0% (1.8-10.1%)                    | 8                    | 27/535         | Random       | 62.42             | .009  |         |
| MRI-guided technique                  | 7.9% (3.7-12.0%)                    | 7                    | 36/396         | Random       | 60.58             | .019  |         |
| Framed navigation                     | 6.0% (4.2-7.7%)                     | 28                   | 141/1991       | Random       | 60.72             | < .001|         |
| Transcerebellar approach              | 3.6% (1.9-5.4%)                     | 11                   | 22/424         | Fixed        | .00               | .433  |         |
| Adult patients                        | 6.8% (2.4-11.2%)                    | 6                    | 23/265         | Random       | 48.52             | .084  |         |
| Pediatric patients                    | 5.1% (3.2-6.9%)                     | 11                   | 36/528         | Fixed        | .00               | .284  |         |
| **Permanent deficits**                |                                     |                      |                |              |                   |       |         |
| CT-guided technique                   | .2% (.0-.7%)                        | 8                    | 1/535          | Fixed        | .00               | .854  |         |
| MRI-guided technique                  | 1.9% (.1-3.7%)                      | 7                    | 13/396         | Random       | 52.21             | .051  |         |
| Framed navigation                     | .4% (.2-.7%)                        | 28                   | 20/1974        | Fixed        | .00               | .627  |         |
| Transcerebellar approach              | .7% (.0-1.5%)                       | 11                   | 1/424          | Fixed        | .00               | .977  |         |
| Adult patients                        | .3% (.0-.7%)                        | 7                    | 1/575          | Fixed        | .00               | .85   |         |
| Pediatric patients                    | .6% (.0-1.3%)                       | 12                   | 1/546          | Fixed        | .00               | .99   |         |
| **Deaths**                            |                                     |                      |                |              |                   |       |         |
| CT-guided technique                   | .4% (.0-.7%)                        | 9                    | 5/942          | Fixed        | .00               | .736  |         |
| MRI-guided technique                  | 1.1% (.1-2.1%)                      | 9                    | 3/343          | Fixed        | .00               | .997  |         |
| Framed navigation                     | .3% (.1-.5%)                        | 32                   | 11/2469        | Fixed        | .00               | .982  |         |
| Transcerebellar approach              | .7% (.0-1.5%)                       | 12                   | 0/450          | Fixed        | .00               | .993  |         |
| Adult patients                        | 1.5% (2-2.8%)                       | 8                    | 3/316          | Fixed        | .00               | .987  |         |
| Pediatric patients                    | .7% (.1-1.3%)                       | 15                   | 1/663          | Fixed        | .00               | .998  |         |

Abbreviations: CT, computerized X-ray tomography; MRI, magnetic resonance imaging.
and the adult patient population shows moderate to substantial heterogeneity.

A lower proportion of permanent deficits (i.e., nonself-limiting damage) than temporary complications occur after the procedure.\textsuperscript{14,28,34} The weighted average proportion of permanent deficits was .5% in the present meta-analysis. The subgroup analysis indicates the similarity of weighted average proportion between the pediatric patient population and the adult patient population but an increased proportion in MRI-guided techniques compared to CT-guided techniques. It is worth mentioning the substantial heterogeneity across all studies included in the subgroup analysis of MRI-guided techniques, which is attributed to the study of Dellaretti et al\textsuperscript{14} that documents the occurrence of permanent deficits in 13 of 123 included patients.

Successful and safe brainstem stereotactic biopsy demands a set of optimal infrastructures, a highly standardized surgical workflow, and an experienced biopsy neurosurgeon.\textsuperscript{41} Nevertheless, procedure-induced mortality is a nonnegligible issue. Indeed, our work demonstrates a very low weighted average proportion of deaths that is merely .3%. The subgroup analysis shows that biopsy with MRI guidance is likely to have larger mortality than biopsy with CT guidance, and biopsy in the adult patient population seems to be more detrimental than biopsy in the pediatric patient population. There may be several reasons why CT-guided biopsy would counterintuitively have lower mortality rates than MRI-guided biopsy. First, CT-guided biopsy may involve larger lesions that do not require MRI and thus are easier to biopsy. Additionally, the CT-guided technique may involve an older series and be more likely to employ framed navigation because frameless navigation is unavailable. Nevertheless, histopathologic biopsy can result in an unequivocal diagnosis and assist in the selection of suitable targeted therapy, indicating that brainstem stereotactic biopsy may optimize the prognosis of patients.

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{fig3}
\caption{Coupled forest plot of the proportion of temporary complications. A binary random-effect model, the Dersimonian Laird method, was used to pool the data because of substantial heterogeneity.}
\end{figure}
The importance of framed navigation and biopsy trajectories influencing the diagnostic yield, complications, and mortality cannot be overlooked. Jaradat et al. recommended that a supratentorial transfrontal approach was indicated for lesions in the midbrain, upper pons, and medulla oblongata, and an infratentorial transcerebellar approach was suitable for lesions within the lower pons. In contrast, a study by Mathon and coworkers highlighted a greater complication rate in the supratentorial transfrontal approach than in the infratentorial transcerebellar approach. In light of this, they proposed that only midbrain lesions should be used for biopsy with a supratentorial transfrontal approach, whereas lesions located within other parts could be safely attained by an infratentorial transcerebellar approach. The diagnostic accuracy and safety may vary from the supratentorial transfrontal approach to the infratentorial transcerebellar approach and from framed navigation to frameless navigation. However, because of the low number of studies with small sample sizes of participants on frameless navigation, transfrontal approach, and transtentorial approach, the diagnostic yield and safety within these subgroups were not available for pooling in our meta-analysis.

Collectively, brainstem stereotactic biopsy is a safe and accurate procedure. CT-guided biopsy has a similar diagnostic yield but low morbidity and mortality to MRI-guided biopsy. The diagnostic accuracy and safety of this procedure are improved in the pediatric patient population compared to the adult patient population. Since the subgroup of 1 single guided technique involves different patient cohorts and vice versa, heterogeneity occurs. Thus, future clinical trials need to validate our findings by comparing the diagnostic yield and safety of CT guidance to that of MRI guidance in the same patient setting and also comparing them in the pediatric patient population.

Figure 4. Coupled forest plot of the proportion of permanent deficits. A binary fixed-effect model, the inverse variance method, was used to pool the data because there was no significant heterogeneity.
and the adult patient population using the same biopsy method.

There are some limitations in this article that deserve a mention. First, the analyzed data in this meta-analysis were binary noncomparative variables, as no available methods were used to calculate the publication bias. Second, the majority of analyzed studies (n = 19) involved smaller sample sizes (< 30 participants), which might give rise to important selection bias. Third, the majority of included studies were performed retrospectively, which indicated other biases due to the data collection and subject selection. More importantly, since there were limited numbers of publications included in the subgroup analyses, the data did not allow us to conduct further subgroup analyses according to different patient cohorts with the same combined assistant technique or distinct guided techniques with the same patient cohort.

Conclusions

Brainstem stereotactic biopsy is an accurate and safe procedure for the diagnosis of brainstem lesions. Alterations in assistant techniques and/or patient populations slightly modify the optimal diagnostic yield and safety. Biopsies targeting the brainstem, as a critical function-related structure, may be associated with higher functional complications or mortality. Our findings may help guide treatment options by elucidating the benefits and risks commonly encountered in neurosurgical practice when performing stereotactic brainstem biopsies.

Figure 5. Coupled forest plot of the proportion of deaths. A binary fixed-effect model, the inverse variance method, was used to pool the data because there was no significant heterogeneity.
Appendix 1

Table A1. Study details for different stereotactic biopsy methods.

| Classifications          | Studies (N) | Event/Total (n/N) | Subgroup Analysis |
|--------------------------|-------------|-------------------|-------------------|
| Diagnostic yield         |             |                   |                   |
| CT-guidance              | 10          | 916/971           | Available         |
| MRI-guidance             | 8           | 295/311           | Available         |
| Frame-based navigation   | 31          | 2444/2541         | Available         |
| Frameless navigation     | 1           | 13/15             | Unavailable       |
| Transcerebellar approach | 13          | 466/479           | Available         |
| Transfrontal approach    | 2           | 50/53             | Unavailable       |
| Transtentorial approach  | 2           | 512/516           | Unavailable       |
| Temporary complications  |             |                   |                   |
| CT-guidance              | 8           | 275/535           | Available         |
| MRI-guidance             | 7           | 36/396            | Available         |
| Frame-based navigation   | 28          | 141/1991          | Available         |
| Frameless navigation     | 1           | 2/15              | Unavailable       |
| Transcerebellar approach | 11          | 22/424            | Available         |
| Transfrontal approach    | 2           | 4/53              | Unavailable       |
| Transtentorial approach  | 2           | 53/516            | Unavailable       |
| Permanent deficits       |             |                   |                   |
| CT-guidance              | 8           | 1/535             | Available         |
| MRI-guidance             | 7           | 13/396            | Available         |
| Frame-based navigation   | 28          | 20/1974           | Available         |
| Frameless navigation     | 1           | 1/15              | Unavailable       |
| Transcerebellar approach | 11          | 1/24             | Available         |
| Transfrontal approach    | 2           | 0/53              | Unavailable       |
| Transtentorial approach  | 2           | 2/516             | Unavailable       |
| Deaths                   |             |                   |                   |
| CT-guidance              | 9           | 5/942             | Available         |
| MRI-guidance             | 9           | 3/434             | Available         |
| Frame-based navigation   | 32          | 11/2469           | Available         |
| Frameless navigation     | 1           | 0/15              | Unavailable       |
| Transcerebellar approach | 12          | 0/450             | Available         |
| Transfrontal approach    | 2           | 0/53              | Unavailable       |
| Transtentorial approach  | 2           | 0/516             | Unavailable       |

Authors’ Contributions

LH, Writing manuscript; Statistical analysis DH, Writing manuscript; Data collection YQ, Writing manuscript, Supervision JZ, Table drawing CY, Figure drawing HC, Validity QW, Supervision GL, Data collection QS, Conception/DesignFinal approval of manuscript. All authors reviewed and approved the manuscript prior to submission.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Lin He  https://orcid.org/0000-0002-7390-1702

References

1. Birski M, Furtak J, Krystkiewicz K, et al. Endoscopic versus stereotactic biopsies of intracranial lesions involving the ventricles. Neurosurg Rev. 2021;44:1721-1727.
2. Gleason CA, Wise BL, Feinstein B. Stereotactic localization (with computerized tomographic scanning), biopsy, and radiofrequency treatment of deep brain lesions. Neurosurgery. 1978;2:217-222.
3. Pereira EAC, Jegan T, Green AL, Aziz TZ. Awake stereotactic brainstem biopsy via a contralateral, transfrontal, transtentorial approach. Br J Neurosurg. 2008;22:599-601.
4. Dellaretti M, Reyns N, Touzet G, et al. Stereotactic biopsy for brainstem tumors: comparison of transcerebellar with
transfrontal approach. *Stereotact Funct Neurosurg.* 2012;90:79-83.

5. Amundson EW, McGirt MJ, Olivi A. A contralateral, transfrontal, extraventricular approach to stereotactic brainstem biopsy procedures. *J Neurosurg.* 2005;102:565-570.

6. Albright AL, Packer RJ, Zimmerman R, Rorke LB, Boyett J, Hammond GD. Magnetic resonance scans should replace biopsies for the diagnosis of diffuse brain stem gliomas. *Neurosurgery.* 1993;33:1026-1030. discussion 1029-1030.

7. Abernathey CD, Camacho A, Kelly PJ. Stereotaxic suboccipital transcerebellar biopsy of pontine mass lesions. *J Neurosurg.* 1989;70:195-200.

8. Coffey RJ, Lunsford DL. Stereotactic surgery for mass lesions of the midbrain and pons. *Neurosurgery.* 1985;17:12-18.

9. Coffey RJ, Lunsford LD. Diagnosis and treatment of brainstem mass lesions by CT-guided stereotactic surgery. *Stereotact Funct Neurosurg.* 1985;48:467-471.

10. Broggi G. Serial stereotactic biopsy of brain stem expanding lesions. Considerations on 45 consecutive cases. *Acta Neurochir Suppl (Wien).* 1988;42:170-176.

11. Giunta F, Marin G, Grasso G, Zorzi F. Brain stem expansive lesions: stereotactic biopsy for a better therapeutic approach. *Acta Neurochir Suppl (Wien).* 1988;42:182-186.

12. Jansen MHA, van Vuurden DG, Vandertop WP, Kaspers GJL. Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology. *Cancer Treat Rev.* 2012;38:27-35.

13. Pincus DW, Richter EO, Yachnis AT, Bennett J, Bhatti MT, Smith A. Brainstem stereotactic biopsy sampling in children. *J Neurosurg Pediatr.* 2006;104:108-114.

14. Dellaretti M, Câmara BBA, Ferreira PHPB, da Silva Júnior JB, Arantes RME. Impact of histological diagnosis on the treatment of atypical brainstem lesions. *Sci Rep.* 2020;10:11065.

15. Buczkoicz P, Hoeman C, Rakopoulos P, et al. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. *Nat Genet.* 2014;46:451-456.

16. Lara-Almuncia M, Hernandez-Vicente J. Frame-based stereotactic biopsy: description and association of anatomical, radiologic, and surgical variables with diagnostic yield in a series of 407 cases. *J Neurol Surg Cent Eur Neurosurg.* 2019;80:149-161.

17. Akay A, İleşkel S. MRI-guided frame-based stereotactic brainstem biopsy procedure: a single-center experience. *Neurocirugía.* 2019;30:167-172.

18. Pirotte BJJM, Lubansu A, Massager N, Wikler D, Goldman S, Levivier M. Results of positron emission tomography guidance and reassessment of the utility of and indications for stereotactic biopsy in children with infiltrative brainstem tumors. *J Neurosurg Pediatr.* 2007;107:392-399.

19. Gupta M, Chan TM, Santiago-Dieppa DR, et al. Robot-assisted stereotactic biopsy of pediatric brainstem and thalamic lesions. *J Neurosurg Pediatr.* 2020;25:1-8.

20. Hamisch C, Kickingereder P, Fischer M, Simon T, Ruge MI. Update on the diagnostic value and safety of stereotactic biopsy for pediatric brainstem tumors: a systematic review and meta-analysis of 735 cases. *J Neurosurg Pediatr.* 2017;20:261-268.

21. Kickingereder P, Williet P, Simon T, Ruge MI. Diagnostic value and safety of stereotactic biopsy for brainstem tumors: a systematic review and meta-analysis of 1480 cases. *Neurosurgery.* 2013;72:873-882. discussion 882; quiz 882.

22. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *PLoS Med.* 2009;6:e1000100.

23. McInnes MDF, Moher D, Thombs BD, et al. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies. *Jama.* 2018;319:388-396.

24. Liang Z, Zhang Q, Wang C, et al. Hyaluronic acid/hyaluronidase as biomarkers for bladder cancer: a diagnostic meta-analysis. *Neoplasma.* 2017;64:901-908.

25. Sutton AJAK, Jones DR. Methods for meta-analysis in medical research. In: *Wiley series in probability and statistics-applied probability and statistics section.* Hoboken: Wiley; 2000.

26. Bahrami E, Parvashre M, Bahrami M, Fattahi A. An experience with frame-based stereotactic biopsy of posterior fossa lesions via transcerebellar route. *World Neurosurg.* 2020;136:e380-e385.

27. Shad A, Green A, Bojanic S, Aziz T. Awake stereotactic biopsy of brain stem lesions: technique and results. *Acta Neurochir.* 2005;147:47-50. discussion 49-50.

28. Puget S, Beccaria K, Blauwblomme T, et al. Biopsy in a series of 130 pediatric diffuse intrinsic pontine gliomas. *Child’s Nerv Syst.* 2015;31:1773-1780.

29. Cheng G, Yu X, Zhao H, et al. Complications of stereotactic biopsy of lesions in the sellar region, pineal gland, and brainstem. *Medicine.* 2020;99:e18572.

30. Dellaretti M, Touzet G, Reyns N, et al. Correlation among magnetic resonance imaging findings, prognostic factors for survival, and histological diagnosis of intrinsic brainstem lesions in children. *J Neurosurg Pediatr.* 2011;8:539-543.

31. Dellaretti M, Touzet G, Reyns N, et al. Correlation between magnetic resonance imaging findings and histological diagnosis of intrinsic brainstem lesions in adults. *Neuro Oncol.* 2012;14:381-385.

32. Cartmill M, Punt J. Diffuse brain stem glioma. A review of stereotactic biopsies. *Child’s Nerv Syst.: ChNS : official journal of the International Society for Pediatric Neurosurgery.* 1999;15:235-238. discussion 238.

33. Wang ZJ, Rao L, Bhambhani K, et al. Diffuse intrinsic pontine glioma biopsy: a single institution experience. *Pediatr Blood Cancer.* 2015;62:163-165.

34. Hamisch CA, Minartz J, Blau T, et al. Frame-based stereotactic biopsy of deep-seated and midline structures in 511 procedures: feasibility, risk profile, and diagnostic yield. *Acta Neurochir.* 2019;161:2065-2071.

35. Ryken TC, Hitchon PW, Roach RM, Traynelis VC. Intratentorial stereotactic biopsy. *Stereotact Funct Neurosurg.* 1992;59:111-114.
36. Puget S, Blauwblomme T, Grill J. Is biopsy safe in children with newly diagnosed diffuse intrinsic pontine glioma? *American Society of Clinical Oncology Educational Book*. 2012;32:629-633.

37. Morais BA, Solla DJF, Matushita H, Teixeira MJ, Monaco BA. Pediatric intrinsic brainstem lesions: clinical, imaging, histological characterization, and predictors of survival. *Child’s Nerv Syst*. 2020;36:933-939.

38. Gupta N, Goumnerova LC, Manley P, et al. Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. *Neuro Oncol*. 2018;20:1547-1555.

39. Kondziolka D, Lunsford LD. Results and expectations with image-integrated brainstem stereotactic biopsy. *Surg Neurol*. 1995;43:558-562.

40. Dawes W, Marcus HJ, Tisdall M, Aquilina K. Robot-assisted stereotactic brainstem biopsy in children: prospective cohort study. *Journal of Robotic Surgery*. 2019;13:575-579.

41. Rachinger W, Grau S, Holtmannspötter M, Herms J, Tonn J-C, Kreth FW. Serial stereotactic biopsy of brainstem lesions in adults improves diagnostic accuracy compared with MRI only. *J Neurol Neurosurg Psychiatr*. 2009;80:1134-1139.

42. Rajshekhar V, Moorthy RK. Status of stereotactic biopsy in children with brain stem masses: insights from a series of 106 patients. *Stereotact Funct Neurosurg*. 2010;88:360-366.

43. Gonçalves-Ferreira AJ, Herculano-Carvalho M, Pimentel J. Stereotactic biopsies of focal brainstem lesions. *Surg Neurol*. 2003;60:311-320. discussion 320.

44. Valdés-Gorcia J, Espinoza-Díaz D, Paredes-Díaz E. Stereotactic biopsy of brain stem and posterior fossa lesions in children. *Acta Neurochir*. 1998;140:899-903.

45. Samadani U, Stein S, Moonis G, Sonnad SS, Bonura P, Judy KD. Stereotactic biopsy of brain stem masses: Decision analysis and literature review. *Surg Neurol*. 2006;66:484-490. discussion 491.

46. Quick-Weller J, Lescher S, Bruder M, et al. Stereotactic biopsy of brainstem lesions: 21 years experiences of a single center. *J Neuro Oncol*. 2016;129:243-250.

47. Manoj N, Arivazhagan A, Bhat DI, et al. Stereotactic biopsy of brainstem lesions: techniques, efficacy, safety, and disease variation between adults and children: a single institutional series and review. *J Neurosci Rural Pract*. 2014;5:32-39.

48. Steck J, Friedman WA. Stereotactic biopsy of brainstem mass lesions. *Surg Neurol*. 1995;43:563-568. discussion 567-568.

49. Haegelen C, Touzet G, Reyns N, Maurage C-A, Ayachi M, Blond S. Stereotactic robot-guided biopsies of brain stem lesions: Experience with 15 cases. *Neurochirurgie*. 2010;56:363-367.

50. Parker F, Levesque MF, Bittoun J, Doyon D, Tadie M. Stereotactic transcerebellar approach to pontine lesions through the middle cerebellar peduncle. *Intervent Neuroradiol*. 1999;5:19-25.

51. Chico-Ponce de León F, Perezpeña-Diazconti M, Castro-Sierra E, et al. Stereotactically-guided biopsies of brainstem tumors. *Child’s Nerv Syst: ChNS: Official Journal of the International Society for Pediatric Neurosurgery*. 2003;19:305-310.

52. Hood TW, Gebarski SS, McKeever PE, Venes JL. Stereotactic biopsy of intrinsic lesions of the brain stem. *J Neurosurg*. 1986;65:172-176.

53. Mathisen JR, Giunta F, Marini G, Backlund E-O. Transcerebellar biopsy in the posterior fossa: 12 years experience. *Surg Neurol*. 1987;28:100-104.

54. Sanai N, Wachhorst SP, Gupta NM, McDermott MW. Transcerebellar stereotactic biopsy for lesions of the brainstem and peduncles under local anesthesia. *Neurosurgery*. 2008;63:460-468. discussion 466-468.

55. Quick-Weller J, Tichy J, Harter PN, et al. “Two is not enough” - impact of the number of tissue samples obtained from stereotactic brain biopsies in suspected glioblastoma. *J Clin Neurosci*. 2018;47:311-314.

56. Yu X, Liu Z, Tian Z. Impact of the number CT-guided stereotactic biopsy of deep brain lesions: report of 310 cases. *Chinese Med J*. 1998;111:361-363.

57. Jaradat A, Nowacki A, Fichtner J, Schlaeppi J-A, Pollo C. Stereotactic biopsies of brainstem lesions: which approach? *Acta Neurochir*. 2021;163:1957-1964.

58. Mathon B, Malaizè H, Amelot A. PSL brain-biopsy study G: stereotactic biopsies of brainstem lesions: dilemma on the best trajectory. *Acta Neurochir*. 2021;163:1957-1964.